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C igarette smoking accounts for more deaths and diseases world-wide than any other modifiable 
risk factor. Indeed, smokers have a two- to 
fourfold increased risk for developing cor-
onary artery disease and stroke.1-3 There 
is also a 25-fold increased risk of lung can-
cer.4 In addition, numerous respiratory 
illnesses, congenital malformations, im-
mune dysfunctions and other co-morbid-
ities are seen more frequently in smokers 
than non-smokers.5
Quitting smoking is extremely difficult 
for most smokers, since nicotine is high-
ly addictive and cessation is associated 
with withdrawal symptoms. To cope with 
withdrawal symptoms and to obtain relief, 
both psychosocial counseling and pharma-
cotherapy are effective methods, but they 
are most effective when used together. 
The first-line pharmacological substances 
licensed to aid smoking cessation are nico-
tine replacement therapy, bupropion and 
varenicline. All these medications are con-
sidered effective and appropriate smoking 
cessation strategies.1,6
Electronic cigarettes (e-cigarettes) 
have the potential of targeting the access 
of nicotine to the brain and thereby to 
prevent the nicotine reinforcing effects.7,8 
Proponents of e-cigarettes insist that e-
cigarettes are healthier than tradition-
al tobacco products and are an effective 
smoking cessation tool. Their supporters 
argue that some electronic nicotine deliv-
ery systems show considerable promise in 
the fight against tobacco-related morbidi-
ty and mortality. Others, however, express 
concerns related to the lack of knowledge 
regarding the long-term effects of e-cig-
arette use, the evidence of toxic chemi-
cal content, the increasing e-cigarette use 
rates among young people, and, finally, 
the lack of government regulation, con-
sumer protection requirements, and prod-
uct quality standards.
Considering the frequent use of e-cig-
arette smoking together with concerns for 
public health, the aim of this review article 
is to highlight the efficacy for smoking ces-
sation and the potential hazards of e-ciga-
rette smoking.
Methods
For this systematic review we searched the 
PubMed electronic database until June 
2015 using as main keyword the term 
“electronic cigarette”, as well as related 
keywords (e-cigarette, electronic nicotine 
delivery systems). We retrieved a total of 
114 publications relevant to research on 
e-cigarette safety/risk profile. The valid-
ity and strength of each study were deter-
mined based on a qualitative assessment 
of study objectives, methods and popula-
tion. In total, 20 original papers and 8 re-
view articles and statements relevant to 
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research on e-cigarette safety/risk profile are cited in 
this review article.
What is the e-cigarette?
The electronic nicotine delivery systems incorporated 
in e-cigarettes are devices in which liquid nicotine is 
heated by a battery, transformed into an aerosol (of-
ten called “vapor”), and inhaled by the user.7,9 Unlike 
traditional cigarettes or other combustible tobacco 
products, e-cigarettes do not contain tobacco, and be-
cause nothing is burned they emit no smoke. It is es-
timated that the e-cigarette devices and liquid used 
deliver one third to one fourth the amount of nico-
tine of smoking one standard cigarette after 5 min-
utes of use (Figure 1).10 New-generation e-cigarette 
devices are more efficient in nicotine delivery but still 
deliver nicotine much more slowly than tobacco ciga-
rettes. It should be noted, however, that e-cigarette 
users do not “smoke” in 5-minute sessions (as with a 
regular cigarette) but may do so over an extended pe-
riod of time, thus potentially absorbing large amounts 
of nicotine.
Since their initial manufacture in 2003, there has 
been rapid growth and evolution in the types, design, 
and overall engineering characteristics of e-cigarettes. 
This has resulted in a large degree of product vari-
ability in size, potential nicotine concentrations, and 
e-liquid formulations. There have also been changes 
in the electrical circuitry (e.g. heating element or at-
omizer) and battery life that allow for more liquid de-
livery, adjustments in flavor, and longer device use. 
Ongoing product development and evolution are like-
ly to continue; therefore, regulatory policies will be 
important to ensure appropriate quality control.7-9,11
E-cigarettes among young individuals
The use of e-cigarettes among young people is grow-
ing. The number of high school students who never 
used tobacco but had tried e-cigarettes tripled be-
tween 2011 and 2013. Some argue that this percent-
age is higher if non-cigarette nicotine delivery devic-
es, such as electronic hookahs or “vape pipes”, are in-
cluded in the count.5
There is also concern among public health ad-
vocates that e-cigarettes could increase nicotine ad-
diction and serve as a gateway to the use of tobacco 
products, particularly among the young. Indeed, al-
though this is debated in the literature, evidence sug-
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Figure 1. Comparison between tobacco cigarette and e-cigarette devices regarding nicotine levels. After 5 minutes of e-cigarette use, 
plasma nicotine levels were substantially lower compared to smoking one tobacco cigarette (almost 3-fold lower for new- and 4-fold lower 
for first-generation devices). Plasma nicotine levels are equal between tobacco cigarette use at 5 minutes and new generation e-cigarette 
device at 35 minutes. (Data from Farsalinos et al10 with permission.)
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gests that the intention to smoke traditional ciga-
rettes is twice as prevalent in young persons who had 
tried e-cigarettes versus nonusers.12 In addition, the 
2011-2013 National Youth Tobacco Survey found 
that, among young people who smoked combustible 
cigarettes, 20% reported that they also had tried e-
cigarettes.13
Potential for smoking cessation (Table 1)
The use of e-cigarettes for the management of tobac-
co dependence is controversial, because of the pau-
city of long-term safety results and randomized, con-
trolled data.14,15 Some argue that e-cigarettes have 
potential as smoking cessation aids and that the de-
vices deliver nicotine to the user without many of 
the harmful constituents found in traditional tobacco 
smoke. An additional advantage, say proponents, is 
that e-cigarettes mimic the tactile and sensory expe-
rience of smoking, giving the quitting process a step-
wise, and thus more easy to adopt, nature. One par-
ticularly large survey reported 81% complete smok-
ing substitution with a median time of e-cigarette use 
of 10 months.16 Furthermore, a longitudinal study 
of e-cigarette use reported that daily users of e-ciga-
rettes were 6 times as likely as nonusers/triers to re-
port quitting.17 The results of EffiCiency and safety of 
an eLectronic cigAreTte (ECLAT), the first prospec-
tive 12-month randomized controlled trial, suggest 
that e-cigarettes help combustible tobacco smokers 
reduce or abstain from use.18 In view of the fact that 
subjects in this study had no immediate intention of 
quitting, the reported overall abstinence rate of 8.7% 
at 52 weeks was remarkable.18 A study by Polosa et 
al, found a sustained 50% reduction in the number 
of cigs/day in 32.5% of smokers who participated in 
a 24-week study. Notably, these participants did not 
originally intend to quit smoking.19
However, others conclude that the potential of 
e-cigarettes to help smokers quit is not clear.20-22 
Bullen et al, compared smoking abstinence rates at 
6 months for those who used e-cigarettes, nicotine 
patches, and placebo e-cigarettes (nicotine-free).23 
Verified abstinence rates at 6 months were 7.3% for 
nicotine e-cigarette users, 5.8% for nicotine patch 
users, and 4.1% for placebo e-cigarette users. This 
study did not demonstrate any superiority of nicotine 
e-cigarettes compared to the other treatments.23 It is 
also impossible to comment on the efficacy of e-ciga-
rettes versus other interventions, such as varenicline 
or bupropion for cessation, given the lack of compar-
ator groups in the studies.24 The World Health Orga-
nization’s 2014 report on e-cigarettes found “insuffi-
cient evidence” to support e-cigarettes as a smoking 
cessation aid and reiterated its recommendation that 
existing approved cessation aids be used.25 A poli-
cy statement from the American Heart Association 
notes that “current evidence suggests a modest effect 
on cessation at best, likely equal to or slightly better 
than nicotine patches without behavioral support”, 
and maintains that further research and regulation is 
urgently needed.13
Are e-cigarettes safe?
Effect on pulmonary function
Although e-cigarettes do not contain as many toxic 
substances as those in cigarette smoke, a recent FDA 
review reported that various chemical substances and 
ultrafine particles known to be toxic, carcinogenic, 
and/or responsible for the causation of respiratory and 
heart distress have been identified in e-cigarette aero-
sols, cartridges, refill liquids, and environmental emis-
sions.4,11 Indeed, the e-cigarette aerosol can cause up-
per respiratory tract irritation, dry cough, dryness of 
the mucous membrane, release of cytokines and pro-
inflammatory mediators, allergic airway inflammation, 
decreased exhaled nitric oxide (FeNO) synthesis in the 
lungs, changes in bronchial gene expression, and a risk 
of lung cancer (Table 2).24 However, further research 
is needed to determine the long-term effects of inhala-
tion of e-cigarette aerosol on lung function.26
Table 1. Efficacy of nicotine vs. non-nicotine e-cigarettes for smoking cessation.
Number of studies OR 95% CI
Abstinence from tobacco smoking 2 2.29 1.05-4.96
Reduce cigarette smoking by at least half (vs. placebo) 2 1.31 1.02-2.68
Reduce cigarette smoking by at least half (vs. NRT) 1 1.41 1.20-1.67
Data are derived from McRobbie et al 201414 and Rahman et al 2015.15 
OR – odds ratio; CI – confidence interval; NRT – nicotine replacement therapy.
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Cardiovascular effects
Few studies have reported the immediate effect of 
e-cigarette use on cardiovascular parameters (Table 
2).27 Mild e-cigarette liquid inhalation is associat-
ed with tachycardia, chest pain and high blood pres-
sure.27,28 More serious events reported are bradycar-
dia, hypotension, respiratory paralysis, atrial fibrilla-
tion and dyspnea.27,28 E-cigarettes increase systolic 
and diastolic blood pressure as well as heart rate, but 
in general, most studies show a smaller magnitude of 
increase compared to traditional cigarette smoking.29 
Furthermore, although smoking acutely causes a de-
lay in myocardial relaxation, e-cigarette use has no 
such immediate effect.30
Although smokeless tobacco-related cardiac events 
have been studied in the past, it is difficult to extrap-
olate data to e-cigarettes, considering their differ-
ent mechanism of nicotine delivery.31 There are also 
currently no published studies on e-cigarette use and 
thrombosis, platelet reactivity and atherosclerosis.32-36 
Preliminary data from our department show that e-
cigarettes increase aortic stiffness.
Nicotine and other chemical substances
Nicotine, which is a highly addictive compound, is de-
livered by most, but not all e-cigarette products.8 Nic-
otine may promote tumor growth, compromise treat-
ment success, and negatively affect the neurological 
development of adolescents.11,24,37 Propylene glycol 
and glycerin are the most common nicotine solvents 
used in e-cigarettes.38 Propylene glycol can irritate 
the eye and respiratory system. Heavy metals, such 
as tin, lead, and nickel, have also been discovered in 
a brand of e-cigarette nicotine liquids and aerosols.39 
These metals can negatively affect the nervous and 
respiratory systems.
Importantly, e-cigarette aerosol contains toxic 
chemicals, such as formaldehyde and acetaldehyde, at 
rates 9 to 450 times lower than those of combustible 
cigarettes and comparable to amounts contained in 
a nicotine inhaler.38,39 Both solvent and battery out-
put voltage significantly affect levels of carbonyl com-
pounds in e-cigarette vapors. New generation high-
voltage e-cigarettes may put their users at increased 
health risk from exposure to high levels of carbonyl 
compounds, although the risk will still probably be 
much lower compared with smoking.40
Conclusions
Electronic cigarettes are growing in popularity, but 
their safety and efficacy as a smoking cessation aid 
are not well explored. Some argue that they have the 
potential to reduce tobacco-related morbidity and 
mortality and could be a useful tool for reducing to-
bacco-related harm. Others express concern that the 
health effects of e-cigarette use are unknown, that 
they may appeal to young people, and that they may 
encourage dual use of e-cigarettes and traditional to-
bacco products. E-cigarette use as a tobacco cessa-
tion product is not currently approved by any regu-
Table 2. Effect of e-cigarette smoking on parameters of cardiovascular and pulmonary function. (Modified from Orellana-Barrios et al9 
with permission.)
Effect
Cardiovascular parameters:
Systolic and diastolic BP Significant diastolic BP increase, 
Heart rate Increase after 5 min, lower than traditional cigs 
Systolic and diastolic cardiac function No effect
Vascular function PWV increase, but smaller than traditional cigs, preliminary data
Pulmonary function parameters:
Carbon oxide No impact 
Oxygen saturation No definite effect with contradicting studies
Exhaled NO Immediate decrease 
Airway resistance Significant (18%) increase
Respiratory impedances Significant increase, including nicotine-free solutions
BP – blood pressure; PWV – pulse wave velocity NO – nitric oxide.
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latory body, and a recent FDA-proposed regulation 
signals a possibly harsher FDA position toward the 
e-cigarette industry. Both the World Health Organi-
zation (WHO) and the American Heart Association 
(AHA) reports voiced fears that, rather than help 
get rid of tobacco once and for all, e-cigarettes could 
make smoking culturally acceptable once again. The 
AHA also issued its policy statement on e-cigarettes, 
saying that the devices should be regulated like tobac-
co products by state and local governments, includ-
ing them in smoke-free laws and taxing them to dis-
courage use by teenagers. The majority of the studies 
performed with the aim of assessing the cardiovascu-
lar effects of e-cigarettes are focused on the acute ef-
fects on the heart. Further research is needed to ex-
amine the longer-term safety, potential for long-term 
use and efficacy as a cessation aid. Finally, it cannot 
be overemphasized that it is important to advise all 
smokers to quit smoking traditional cigarettes, en-
courage the use of cessation medications approved by 
regulatory bodies, and refer patients for smoking ces-
sation counseling.
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